(p. A5) “Vaccines are probably the next big thing” in the quest to reduce cancer deaths, said Dr. Steve Lipkin, a medical geneticist at New York’s Weill Cornell Medicine, who is leading one effort funded by the National Cancer Institute. “We’re dedicating our lives to that.”
For the full story, see:
(Note: bracketed date added.)
(Note: the online version of the story was updated Nov 2, 2023, and has the title “The next big advance in cancer treatment could be a vaccine.”)
(p. 13) While recent events have provided a painful reminder of the very bad viruses that prey on us, Tom Ireland’s “The Good Virus” is a colorful redemption story for the oft-neglected yet incredibly abundant phage, and its potential for quelling the existential threat of antibiotic resistance, which scientists estimate might cause up to 10 million deaths per year by 2050. Ireland, an award-winning science journalist, approaches the subject of his first book with curiosity and passion, delivering a deft narrative that is rich and approachable.
In the hands of d’Herelle and others, the phage became a potent tool in the fight against cholera. But, in the 1940s, when the discovery of the methods to produce penicillin at an industrial scale led to the “antibiotic era,” phage therapy came to be seen as quackery in Europe and America, in part, Ireland suggests, because antibiotics, unlike phages, fit the mold of capitalist society.
Capitalists love patents. A funny quirk of the patent system is that you cannot patent entire natural things, but you can sometimes patent the way you extract their byproducts. The first antibiotics, being the secretions of fungi, were easier to patent in the United States than phages, which were whole viruses.
For the full review, see:
Alex Johnson. “Going Viral.” The New York Times Book Review (Sunday, September 17, 2023): 13.
(Note: the online version of the review has the date Aug. 15, 2023, and has the title “A Reason to Cheer for Cells and the Viruses That Feed on Them.”)
The book under review is:
Ireland, Tom. The Good Virus: The Amazing Story and Forgotten Promise of the Phage. New York: W. W. Norton & Company, 2023.
(p. 9) At various moments in “Elon Musk,” Walter Isaacson’s new biography of the world’s richest person, the author tries to make sense of the billionaire entrepreneur he has shadowed for two years — sitting in on meetings, getting a peek at emails and texts, engaging in “scores of interviews and late-night conversations.” Musk is a mercurial “man-child,” Isaacson writes, who was bullied relentlessly as a kid in South Africa until he grew big enough to beat up his bullies. Musk talks about having Asperger’s, which makes him “bad at picking up social cues.”
. . .
At one point, Isaacson asks why Musk is so offended by anything he deems politically correct, and Musk, as usual, has to dial it up to 11. “Unless the woke-mind virus, which is fundamentally anti-science, anti-merit and anti-human in general, is stopped,” he declares, “civilization will never become multiplanetary.”
. . .
The musician Grimes, the mother of three of Musk’s children (. . .), calls his roiling anger “demon mode” — a mind-set that “causes a lot of chaos.” She also insists that it allows him to get stuff done.
. . .
He is mostly preoccupied with his businesses, where he expects his staff to abide by “the algorithm,” his workplace creed, which commands them to “question every requirement” from a department, including “the legal department” and “the safety department”; and to “delete any part or process” they can. “Comradery is dangerous,” is one of the corollaries. So is this: “The only rules are the ones dictated by the laws of physics. Everything else is a recommendation.”
Still, Musk has accrued enough power to dictate his own rules. In one of the book’s biggest scoops, Isaacson describes Musk secretly instructing his engineers to “turn off” Starlink satellite internet coverage to prevent Ukraine from launching a surprise drone attack on Russian forces in Crimea. (Isaacson has since posted on X that contrary to what he writes in the book, Musk didn’t shut down coverage but denied a request to extend the network’s range.)
. . .
Isaacson believes that Musk wanted to buy Twitter because he had been so bullied as a kid and “now he could own the playground.” . . . Owning a playground won’t stop you from getting bullied.
For the full review, see:
(Note: ellipses added.)
(Note: the online version of the review was updated Sept. 11, 2023, and has the title “Elon Musk Wants to Save Humanity. The Only Problem: People.”)
The book under review is:
Isaacson, Walter. Elon Musk. New York: Simon & Schuster, 2023.
(p. 20) Charles Barber’s “In the Blood” treats a consequential topic, and contains moments of real insight, drama and humor.
. . .
Though hemorrhage is a leading cause of death in both war and peacetime, we learn, the techniques for stopping it haven’t improved significantly for millenniums. Barber explores the mysteries of the “coagulation cascade” — during which diverse proteins activate in intricately choreographed sequence to facilitate clotting — as well as the “lethal triad” of hypothermia, acidosis and coagulopathy (impaired clotting) that can send the body into shock.
We watch a surgeon at a Navy hospital in Bethesda slit the femoral arteries of a herd of 700-pound pigs, then apply different hemostatic agents to the spurting wounds, to see which substance stops the bleeding best. Most products, backed by biotech and medical companies, fail: The poor beasts bleed out. But zeolite, a simple mineral with hitherto unknown hemostatic properties, saves their bacon every time.
Barber’s earlier books feature persistent, plucky outsiders who strive to change the world, and he finds two more likely subjects in the men who brought zeolite’s lifesaving properties to light. Frank Hursey is the brilliant, nerdy engineer who discovers that this cheap, highly porous mineral, used by industry to absorb radiation, chemicals and bad odors, also happens to accelerate clotting, by mopping up water in the blood and thereby concentrating its coagulation agents. (Later Hursey finds that another inexpensive mineral, kaolin, works even better.)
Barely anyone pays attention to Hursey’s discovery until he partners with Bart Gullong, a down-on-his-luck salesman who rebrands Hursey’s invention “QuikClot” and persuades a military scientist to try it out on people. Hursey and Gullong are soon befriended by iconoclasts within the armed forces medical establishment, more of Barber’s appealing, quirky, determined Davids, who together take on two of the biggest Goliaths around: the military-industrial complex and Big Pharma.
For the full review, see:
Tom Mueller. “The Home Front.” The New York Times (Sunday, Aug. 20, 2023): 20.
(Note: ellipsis added.)
(Note: the online version of the review has the date July 26, 2023, and has the title “A Fight to Save Soldiers, From the Lab to the Battlefield.”)
The book under review is:
Barber, Charles. In the Blood: How Two Outsiders Solved a Centuries-Old Medical Mystery and Took on the Us Army. New York: Grand Central Publishing, 2023.
(p. C7) As engaging as it is expansive, “The Good Virus” describes the distinctive biology and murky history of bacteriophage (generally shortened to “phage”), a form of life that is remarkably abundant yet obscure enough to have been termed the “dark matter of biology.”
. . .
In a South London research institute in the early 1910s, the meticulous English bacteriologist Frederick Twort set out to grow the smallpox virus in petri dishes, hoping it could be “observed and studied like bacteria.” He succeeded in growing only contaminating bacteria, but within these colonies he noticed the occasional small clearing, as if something invisible was killing the bacteria. With the outbreak of World War I, Twort lost funding, closed his lab and published his results in 1915, cautiously suggesting that a virus could be the cause of the observed phenomenon. Few took notice.
Twort’s unlikely competitor would be Felix d’Herelle, a free-spirited Frenchman . . .
. . .
He found the same glassy spots that Twort had observed and (with noticeably less restraint) announced in 1917 that he had discovered a new form of life, which he called “bacteriophage.” D’Herelle went on to use phage to treat five sick boys successfully. But his “wild and abrasive style” (in Mr. Ireland’s words) antagonized his peers, who conspired to undermine him.
D’Herelle’s discoveries inspired many, including George Eliava, a microbiologist from the Soviet Union’s republic of Georgia. In 1936, he would establish the first institute (and still one of the few) devoted to bacteriophage research. Unfortunately for Eliava, he soon ran afoul of the Soviet secret police, who disappeared him in 1937. The institute continued to pursue the development of phage therapy and scored many victories—phage helped treat soldiers suffering from gangrene, for example. But there were also frustrating failures, in part because the phage weren’t adequately purified and often because they weren’t appropriately matched to the specific strain of infecting bacteria.
. . .
. . ., the “dubious and unreliable nature of commercial American phage products” in the 1930s, we learn, meant that “whether they worked for a particular patient was a complete lottery.”
During World War II, the West turned decisively to newly discovered penicillin, sharing the formula for it with the Soviets but not the methods of mass production. Thus the Soviets continued to rely on phage as the therapy of choice for bacterial infections. When a Soviet researcher tried to obtain production rights to penicillin in 1949, he was arrested by government authorities and died under interrogation, all for the crime of nizkopoklonstvo—adulation of the West.
. . .
Once “derided as an idea for cranks and commies,” Mr. Ireland writes, phage therapy seems to be enjoying a renaissance. Having been sustained for years by an idiosyncratic global community of true believers, phage-based medicines have now attracted the attention of high-powered biotechnologists and investors.
For the full review, see:
David A. Shaywitz. “The Enemy of My Enemy.” The Wall Street Journal (Saturday, Aug. 5, 2023): C7.
(Note: ellipses added. In the original, the Russian word nizkopoklonstvo is in italics.)
(Note: the online version of the review has the date August 4, 2023, and has the title “‘The Good Virus’ Review: An Unlikely Healer.”)
The book under review is:
Ireland, Tom. The Good Virus: The Amazing Story and Forgotten Promise of the Phage. New York: W. W. Norton & Company, 2023.
(p. A13) Make no mistake—Mr. Myhrvold is concerned about climate change. . . .
He laments that policy makers largely scorn geoengineering—human interventions in the Earth’s natural systems to thwart or neutralize climate change.
. . .
Geoengineering is about “deliberately trying to reduce climate change.” Excess CO2 traps a little less than 1% of heat from the sun, “so if we could make the sun 1% dimmer, we could shut off climate change.” When Mount Pinatubo, a volcano in the Philippines, erupted in 1991, it lowered world-wide temperatures by 1 degree Celsius for about 18 months. Human-emitted particulate pollution has historically offset about 20% of human-emitted CO2. “Ironically,” he says, “the Clean Air Act made our air better but hurt climate change.”
The simplest solar-radiation management scheme, Mr. Myhrvold says, “is to emit particles in the stratosphere to mimic Mount Pinatubo. We invented a particularly elegant way to do this with balloons and a pipe to the sky.” By “we,” he means Intellectual Ventures, the company Mr. Myhrvold founded in 2000 after leaving Microsoft, where he spent 13 years and rose to the position of chief technology officer. Intellectual Ventures “creates, incubates and commercializes” new inventions.
“Marine cloud brightening” is another solar-related intervention. “The idea is to increase the number and size of low clouds that form over the oceans so that more incoming sunlight bounces back into space instead of heating the ocean.” Scientists have proposed a variety of ways to do this. One, which Mr. Myhrvold’s company has explored, is to outfit ships with equipment to spray seawater into the air as they traverse the ocean. “The salt particles can serve as nuclei for water vapor to condense into droplets, thus forming clouds.”
. . .
“Opponents worry that once you have geoengineering, people won’t make sacrifices to cut emissions. They want a sword of Damocles hanging over humanity as a means to force us to follow their ideology.”
Mr. Myhrvold uses an analogy he describes as “horrible in some ways.” When the AIDS epidemic hit, some people saw it as punishment from God. “Their attitude was, ‘This is what you get if you indulge in the practices we don’t approve of.’ ” In climate change, he says, this moralistic attitude takes the following form: “I don’t like aspects of our society, I don’t like technology, I don’t like capitalism, and this is nature’s retribution. And so we have to change the way we live.” Such beliefs “have become a very powerful disincentive, particularly for academic researchers.”
. . .
“You could imagine a world in which cardiology doesn’t exist because the medical profession said, ‘You fat bastards. You did it to yourselves. We’re not going to help you.’ ”
For the full interview, see:
(Note: ellipses added.)
(Note: the online version of the interview has the date February 17, 2023, and has the title “THE WEEKEND INTERVIEW; Emission Cuts Will Fail to Stop Climate Change. What to Do Then?”)
(p. A2) Patrick Collison, the Irish-born co-founder of payments technology company Stripe Inc., has spent a lot of the past five years pondering the problem of declining scientific productivity.
. . .
Clearly, scientific productivity has something to do with how research is done, not how much. One culprit, in the view of Mr. Collison and many others, is that the institutions that fund science have become process-oriented, narrow-minded and risk-averse. Wary of failure, they favor established researchers pursuing narrowly focused, incremental ideas over younger scientists with more heterodox agendas.
. . .
Yet Mr. Collison criticizes the federal government for failing to bring a much deeper and eager pool of talent to bear on a multitude of pandemic challenges. Top virologists “were stuck on hold, waiting for decisions about whether they could repurpose their existing funding for this exponentially growing catastrophe,” he wrote in an essay last year with George Mason University economist Tyler Cowen, and University of California, Berkeley bioengineering professor Patrick Hsu.
Sensing a need, the three in April, 2020 launched Fast Grants, $10,000 to $500,000 awards funded primarily by private donors and approved in 14 days or less.
. . .
When Messrs. Collison, Cowen and Tsu surveyed their recipients about their experiences with traditional funding, 57% told them they spent more than a quarter of their time on grant applications and 78% said they would change their research program a lot if they weren’t constrained in how they spent their current funding.
This reinforces a key insight from metascience, also known as the science of science, namely the value of curiosity-driven research. Heidi Williams, an economist at Stanford University and director of science policy at the Institute for Progress, said grants typically commit a scholar to complete a specific project, even if during the research the project proves less promising than expected.
. . .
In a 2009 paper, Massachusetts Institute of Technology economist Pierre Azoulay and his co-authors demonstrated the benefits of funding people over projects. Researchers backed by the Howard Hughes Medical Institute, which takes such an approach, produce far more widely cited papers—a metric of significance—than similar researchers funded by the National Institutes of Health. Drawing on those lessons, last year, Mr. Collison co-founded the Arc Institute to pre-fund scientists studying complex human diseases for renewable eight-year terms.
For the full commentary, see:
(Note: ellipses added.)
(Note: the online version of the commentary has the date November 17, 2022, and has the title “CAPITAL ACCOUNT; Stagnant Scientific Productivity Holding Back Growth.”)
The published version of Azoulay’s co-authored 2009 NBER working paper, mentioned above, is:
Azoulay, Pierre, Joshua S. Graff Zivin, and Gustavo Manso. “Incentives and Creativity: Evidence from the Academic Life Sciences.” RAND Journal of Economics 42, no. 3 (Fall 2011): 527-54.
(p. 6) . . . an engineer named Blake Lemoine . . . worked on artificial intelligence at Google, specifically on software that can generate words on its own — what’s called a large language model. He concluded the technology was sentient; his bosses concluded it wasn’t.
. . .
There is no evidence this technology is sentient or conscious — two words that describe an awareness of the surrounding world.
That goes for even the simplest form you might find in a worm, said Colin Allen, a professor at the University of Pittsburgh who explores cognitive skills in both animals and machines. “The dialogue generated by large language models does not provide evidence of the kind of sentience that even very primitive animals likely possess,” he said.
Alison Gopnik, a professor of psychology who is part of the A.I. research group at the University of California, Berkeley, agreed. “The computational capacities of current A.I. like the large language models,” she said, “don’t make it any more likely that they are sentient than that rocks or other machines are.”
. . .
(p. 7) “A conscious organism — like a person or a dog or other animals — can learn something in one context and learn something else in another context and then put the two things together to do something in a novel context they have never experienced before,” Dr. Allen of the University of Pittsburgh said. “This technology is nowhere close to doing that.”
For the full story, see:
(Note: ellipses added.)
(Note: the online version of the story was updated Aug. 11 [sic.], 2022, and has the title “A.I. Is Not Sentient. Why Do People Say It Is?”)
(p. B1) The electric vehicle revolution is nearly here, but its arrival is being slowed by a fundamental problem: The chargers where people refuel these cars are often broken. One recent study found that about a quarter of the public charging outlets in the San Francisco Bay Area, where electric cars are commonplace, were not working.
. . .
Many sit in parking lots or in (p. B3) front of retail stores where there is often no one to turn to for help when something goes wrong. Problems include broken screens and buggy software. Some stop working midcharge, while others never start in the first place.
Some frustrated drivers say the problems have them second-guessing whether they can fully abandon gas vehicles, especially for longer trips.
“Often, those fast chargers have real maintenance issues,” said Ethan Zuckerman, a professor at the University of Massachusetts Amherst who has owned a Chevrolet Bolt for several years. “When they do, you very quickly find yourself in pretty dire straits.”
In the winter of 2020, Mr. Zuckerman was commuting about 150 miles each way to a job at the Massachusetts Institute of Technology. The cold winter weather can reduce the driving range of electric cars, and Mr. Zuckerman found himself needing a charge on the way home.
He checked online and found a station, but when he pulled up to it, the machine was broken. Another across the street was out, too, he said. In desperation, Mr. Zuckerman went to a nearby gas station and persuaded a worker there to run an extension cord to his car.
“I sat there for two and a half hours in the freezing cold, getting enough charge so that I could limp to the town of Lee, Mass., and then use another charger,” he said. “It was not a great night.”
The availability and reliability of public chargers remains a problem even now, he said.
. . .
There are few rigorous studies of charging stations, but one conducted this year by Cool the Earth, an environmental nonprofit in California, and David Rempel, a retired professor of bioengineering at the University of California, Berkeley, found that 23 percent of 657 public charging stations in the Bay Area were broken. The most common problems were that testers could not get chargers to accept payment or initiate a charge. In other cases, screens went blank, were not responsive or displayed error messages.
“Here we have actual field data, and the results, frankly, were very concerning,” said Carleen Cullen, executive director of Cool the Earth.
. . .
At most gas stations, a clerk is usually on duty and can see when some problems arise. With chargers, vandalism or other damage can be more difficult to track.
“Where there’s a screen, there’s a baseball bat,” said Jonathan Levy, EVgo’s chief commercial officer.
For the full story, see:
(Note: ellipses added.)
(Note: the online version of the story has the same date as the print version, and has the title “A Frustrating Hassle Holding Electric Cars Back: Broken Chargers.”)
(p. B10) Dr. Raymond Damadian, who built the first magnetic resonance imaging scanner, which revolutionized doctors’ ability to diagnose cancer and other illnesses — but who, to his dismay, saw the Nobel Prize for the science behind it go to two others — died on Aug. 3 [2022] at his home in Woodbury, N.Y.
. . .
The vision of scanning the human body without radiation came to Dr. Damadian in the late 1960s, he said, when he was working on nuclear magnetic resonance spectroscopy — which, until then, had been used to identify the chemical makeup of the contents of a test tube — at Downstate Medical Center (now SUNY Downstate Health Sciences University) in Brooklyn.
Working with rats, he discovered that when tissues were placed in a magnetic field and hit with a pulse of radio waves, cancerous ones emitted distinctly different radio signals than healthy ones.
He published his findings in 1971 in the journal Science and was granted a patent three years later for an “apparatus and method for detecting cancer in tissue.” It took 18 months to build the first M.R.I., originally known as a nuclear magnetic resonance scanner, or N.M.R. Its first scan, on July 3, 1977, was of Lawrence Minkoff, one of Dr. Damadian’s assistants — a vivid and colorful image of his heart, lungs, aorta, cardiac chamber and chest wall.
“Having birthed the original idea of the N.M.R. body scanner, we were intent on being the first to accomplish it,” Dr. Damadian said in the book “Gifted Mind: The Dr. Raymond Damadian Story, Inventor of the M.R.I.,” published in 2015, which he wrote with Jeff Kinley. “Failing to do so meant we might be denied the recognition for the original idea.”
But the technology behind the M.R.I. had several fathers.
Acknowledging that he was inspired by Dr. Damadian’s work, Paul C. Lauterbur of the State University of New York at Stony Brook had figured out how to translate the radio signals bounced off tissue into images. And Peter Mansfield of the University of Nottingham in England had developed mathematical techniques for analyzing the data, making the process more practical.
Employing the techniques he pioneered, Dr. Damadian’s company, Fonar, based in Melville, N.Y., produced the first commercial scanner in 1980.
. . .
While working at Downstate and later at Fonar, Dr. Damadian was aware of Dr. Lauterbur, a chemist who was also working on M.R.I. imaging and with whom he shared the National Medal of Technology.
In “Gifted Mind,” Dr. Damadian acknowledged that Dr. Lauterbur “realized that the N.M.R. signal differences in diseased and normal tissues I discovered could be used to construct a picture (image).”
But in 2003, when Dr. Lauterbur and Dr. Mansfield won the Nobel Prize in Medicine for their contributions to the science of magnetic resonance imaging, Dr. Damadian was enraged.
. . .
A year later, Dr. Damadian received one of the two annual Bower Awards given by the Franklin Institute, a science museum in Philadelphia. He was cited for his business leadership.
“There is no controversy in this,” said Dr. Bradford A. Jameson, a professor of biochemistry at Drexel University who was the chairman of the committee that chose the winners. “If you look at the patents in this field, they’re his.”
. . .
Dr. Damadian continued to innovate. He created open M.R.I. machines, which alleviate the claustrophobia patients can experience during scans when they are moved slowly through a tight tunnel, as well as mobile and stand-up scanners.
In recent years, he was focused on research that included imaging cerebral spinal fluid as it flowed to the brain.
For the full obituary, see:
(Note: ellipses, and bracketed year, added.)
(Note: the online version of the obituary was updated Aug. 19, 2022, and has the title “Raymond Damadian, Creator of the First M.R.I. Scanner, Dies at 86.” Where there is a minor difference between the online and print versions, the passages quoted above follow the online version.)
Damadian’s biography mentioned above is:
Kinley, Jeff, and Raymond Damadian. Gifted Mind: The Dr. Raymond Damadian Story, Inventor of the MRI. Green Forest, AZ: Master Books, 2015.
(p. A17) In his last year as vice president, Joe Biden launched a “cancer moonshot” to accelerate cures for the disease. It was short-lived, but he did help negotiate an agreement in Congress easing regulation of breakthrough drugs and medical devices.
In February [2022], President Biden revived the initiative, setting a goal of reducing cancer death rates by at least 50% over the next 25 years. It’s ambitious but may be achievable given how rapidly scientific knowledge and treatments are advancing. Other Biden policies, however, are at odds with the goals of this one.
Two pharmaceutical breakthroughs were announced only last week that could save tens of thousands of lives each year and redefine cancer care. Yet the tax hikes and drug-price controls that the Biden administration is pitching would discourage the private investment that has delivered these potential cures.
. . .
Oncologists were blown away by the results reported last week in the New England Journal of Medicine: All 12 patients receiving the drug achieved complete remission after six months of treatment. None needed surgery, chemotherapy or radiation. Although some may relapse, the 100% success rate is unprecedented even for a small trial.
. . .
Last week AstraZeneca in partnership with Daiichi Sankyo reported that Enhertu reduced the risk of death by 36% in patients with metastatic breast cancer with low HER2 and by half for the subset who were hormone-receptor negative. These results blow the outcomes for other metastatic breast-cancer therapies out of the water.
. . .
These treatment breakthroughs aren’t happening because of government programs. They’re happening because pharmaceutical companies have invested decades and hundreds of billions of dollars in drug research and development. It typically takes 10.5 years and $1.3 billion to bring a new drug to market. About 95% of cancer drugs fail.
This is important to keep in mind as Mr. Biden and Democrats in Congress push for Medicare to “negotiate”—i.e., cap—drug prices and raise taxes on corporations and investors. The large profits that drugmakers notch from successful drugs are needed to reward shareholders for their investment risk and encourage future investment. Capital is mobile.
Mr. Biden’s proposal to increase the top marginal individual income-tax rates, including on capital gains, would punish venture capitalists who seed biotech startups, which do most early-stage research on cancer drugs and are often acquired by large drugmakers. At the same time, his proposed corporate global minimum tax would raise costs of intellectual property, which is often taxed at lower rates abroad.
There aren’t many things to celebrate nowadays, but biotech innovation is one. Let’s hope the president doesn’t kill his own cancer moonshot.
For the full commentary see:
(Note: ellipses, and bracketed year, added.)
(Note: the online version of the commentary has the date June 15, 2022, and has the same title as the print version.)
